1. Monash Health
  2. Monash Health research
  3. Articles
Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/27204
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBrown M.R.en
dc.contributor.authorVajdic C.M.en
dc.contributor.authorDelaney G.P.en
dc.contributor.authorHong S.en
dc.contributor.authorHunt L.en
dc.contributor.authorWebber K.en
dc.contributor.authorPearson S.-A.en
dc.contributor.authorVan Leeuwen M.T.en
dc.contributor.authorLuu S.en
dc.contributor.authorGurney H.en
dc.date.accessioned2021-05-14T09:07:01Zen
dc.date.available2021-05-14T09:07:01Zen
dc.date.copyright2021en
dc.date.created20210224en
dc.date.issued2021-02-24en
dc.identifier.citationJNCI Cancer Spectrum. 4 (6) (no pagination), 2021. Article Number: pkaa076. Date of Publication: 2021.en
dc.identifier.issn2515-5091 (electronic)en
dc.identifier.urihttps://repository.monashhealth.org/monashhealthjspui/handle/1/27204en
dc.description.abstractBackground: Several targeted therapies for cancer have been associated with cardiovascular toxicity. The evidence for this association has not been synthesized systematically nor has the quality of evidence been considered. We synthesized systematic review evidence of cardiovascular toxicity of individual targeted agents. Method(s): We searched MEDLINE, Embase, and the Cochrane Database of Systematic Reviews for systematic reviews with meta-analyses of cardiovascular outcomes for individual agents published to May 2020. We selected reviews according to prespecified eligibility criteria (International Prospective Register of Systematic Reviews CRD42017080014). We classified evidence of cardiovascular toxicity as sufficient, probable, possible, or indeterminate for specific cardiovascular outcomes based on statistical significance, study quality, and size. Result(s): From 113 systematic reviews, we found at least probable systematic review evidence of cardiovascular toxicity for 18 agents, including high- and all-grade hypertension for bevacizumab, ramucirumab, axitinib, cediranib, pazopanib, sorafenib, sunitinib, vandetanib, aflibercept, abiraterone, and enzalutamide, and all-grade hypertension for nintedanib; high- and all-grade arterial thromboembolism (includes cardiac and/or cerebral events) for bevacizumab and abiraterone, high-grade arterial thromboembolism for trastuzumab, and all-grade arterial thromboembolism for sorafenib and tamoxifen; high- and all-grade venous thromboembolism (VTE) for lenalidomide and thalidomide, high-grade VTE for cetuximab and panitumumab, and all-grade VTE for bevacizumab; high- and all-grade left ventricular ejection fraction decline or congestive heart failure for bevacizumab and trastuzumab, and all-grade left ventricular ejection fraction decline/ congestive heart failure for pazopanib and sunitinib; and all-grade corrected QT interval prolongation for vandetanib. Conclusion(s): Our review provides an accessible summary of the cardiovascular toxicity of targeted therapy to assist clinicians and patients when managing cardiovascular health.Copyright © 2020 Oxford University Press. All rights reserved.en
dc.languageEnglishen
dc.languageenen
dc.publisherOxford University Pressen
dc.relation.ispartofJNCI Cancer Spectrum-
dc.titleCardiovascular toxicity of targeted therapies for cancer: An overview of systematic reviews.en
dc.typeReviewen
dc.type.studyortrialSystematic review and/or meta-analysis-
dc.identifier.doihttp://monash.idm.oclc.org/login?url=-
dc.identifier.doihttp://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1093/JNCICS/PKAA076en
dc.publisher.placeUnited Kingdomen
dc.identifier.source2011008604en
dc.identifier.institution(Van Leeuwen, Luu, Pearson, Hong, Vajdic) Centre for Big Data Research in Health, University of New South Wales, Sydney, NSW, Australia (Gurney, Brown) Faculty of Medicine and Health Sciences, Macquarie University, Sydney, NSW, Australia (Webber) Department of Oncology, Monash Health, Clayton, VIC, Australia (Webber) School of Clinical Sciences, Monash University, Clayton, VIC, Australia (Hunt) Cancer Voices NSW, Milsons Point, New South Wales, Australia (Hong) Division of Oncology-Haematology, Department of Internal Medicine, National Health Insurance Service Ilsan Hospital, Goyang, South Korea (Delaney) Liverpool Cancer Therapy Centre, Liverpool, NSW, Australia (Delaney) Collaboration for Cancer Outcomes Research and Evaluation, Ingham Institute for Applied Medical Research, Liverpool, NSW, Australia (Delaney) South Western Sydney Clinical School, University of New South Wales, Liverpool, NSW, Australiaen
dc.description.addressM.T. Van Leeuwen, Centre for Big Data Research in Health, University of New South Wales, Sydney, NSW 2052, Australia. E-mail: m.vanleeuwen@unsw.edu.auen
dc.description.publicationstatusEmbaseen
dc.rights.statementCopyright 2021 Elsevier B.V., All rights reserved.en
dc.identifier.authoremailVan Leeuwen M.T.; m.vanleeuwen@unsw.edu.auen
dc.identifier.affiliationext(Van Leeuwen, Luu, Pearson, Hong, Vajdic) Centre for Big Data Research in Health, University of New South Wales, Sydney, NSW, Australia-
dc.identifier.affiliationext(Gurney, Brown) Faculty of Medicine and Health Sciences, Macquarie University, Sydney, NSW, Australia-
dc.identifier.affiliationext(Webber) School of Clinical Sciences, Monash University, Clayton, VIC, Australia-
dc.identifier.affiliationext(Hunt) Cancer Voices NSW, Milsons Point, New South Wales, Australia-
dc.identifier.affiliationext(Hong) Division of Oncology-Haematology, Department of Internal Medicine, National Health Insurance Service Ilsan Hospital, Goyang, South Korea-
dc.identifier.affiliationext(Delaney) Liverpool Cancer Therapy Centre, Liverpool, NSW, Australia-
dc.identifier.affiliationext(Delaney) Collaboration for Cancer Outcomes Research and Evaluation, Ingham Institute for Applied Medical Research, Liverpool, NSW, Australia-
dc.identifier.affiliationext(Delaney) South Western Sydney Clinical School, University of New South Wales, Liverpool, NSW, Australia-
dc.identifier.affiliationmh(Webber) Department of Oncology, Monash Health, Clayton, VIC, Australia-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.openairetypeReview-
Appears in Collections:Articles
Show simple item record

Page view(s)

24
checked on Sep 11, 2024

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.